公开(公告)号：US20120238617A1

公开(公告)日：2012-09-20

申请号：US13394530

申请日：2010-09-06

申请人： Massimiliano Pagani ,  Raffaele De Francesco ,  Grazisa Rossetti ,  Sergio Abrignani ,  Riccardo Lorenzo Rossi

发明人： Massimiliano Pagani ,  Raffaele De Francesco ,  Grazisa Rossetti ,  Sergio Abrignani ,  Riccardo Lorenzo Rossi

IPC分类号： C12Q1/68 ,  A61P35/00 ,  A61P1/16 ,  A61K31/7105

CPC分类号： C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/178

摘要： A method for diagnosing or prognosticating hepatocellular carcinoma, also in the early stages, or for assessing the risk of developing hepatocellular carcinoma, or for monitoring the effectiveness of an anti-tumour therapy against hepatocellular carcinoma by measuring the expression level of at least one miRNA gene product in a peripheral blood sample or in a biological fluid sample. Said method comprises measuring, in an isolated sample of peripheral blood or biological fluid, the expression level of at least one miRNA gene product, and comparing said measured expression level with a reference level. Such method can also be used to diagnose or assess the risk of developing liver cirrhosis in patients affected by chronic hepatitis, or to prognosticate the evolution of cirrhosis in patients affected by cirrhosis, or to monitor the effectiveness of a pharmacological therapy against liver cirrhosis.

摘要翻译： 用于诊断或预后的肝细胞癌的方法，也可在早期阶段，或用于评估发展中的肝细胞癌的风险，或通过测量至少一种miRNA基因的表达水平监测抗肿瘤治疗对肝细胞癌的有效性 产品在外周血样品或生物流体样品中。 所述方法包括在外周血液或生物流体的分离样品中测量至少一种miRNA基因产物的表达水平，并将所述测量的表达水平与参考水平进行比较。 这种方法也可用于诊断或评估慢性肝炎患者发生肝硬化的风险，或预测肝硬化患者肝硬化的进展情况，或监测药物治疗对肝硬化的有效性。